Flamel Technologies SA

Main Activity in Nanotechnology

Material Manufacturer

About Company

Flamel Technologies has invented two innovative polymer-based technologies:

• Micropump® for the delivery of small molecule drugs, including pediatric and geriatric uses.
• Medusa® for the delivery of native protein drugs.

Flamel provides tailored solutions to the industry for optimized controlled-released delivery of drugs. The Company turns already-marketed or new drugs into more effective and safer medicines. Well advanced and rich products pipeline:

• Genvir™,
• Metformin XL,
• Basulin®,
• IFNalpha-2b XL,
• IL-2, hGH and
• EPO.

The Company has assembled a strong team of researchers expert in polymer science and biochemistry, including more than 35 Ph.D.s.

Flamel is helped in its innovative research and development work by three world renown scientists: Pierre-Gilles de Gennes (Nobel Laureate in Physics in 1991), Jean-Marie Lehn (Nobel Laureate in Chemistry in 1987) and Sir John Vane (Nobel Laureate in Physiology of Medicine in 1982).

The Company owns a 50,000-square foot pharmaceutical production facility located in Pessac, France (with an annual production capacity of 2 billion tablets or capsules).

The Pessac facility and its operation are approved by the European drug agencies and are in substantial compliance with "Good Manufacturing Practice" ("cGMP"). The facility provides Flamel with the capability to manufacture its cGMP-grade pharmaceutical drugs for clinical trials utilizing its Micropump® or Medusa® technologies.